Last reviewed · How we verify
OxyNorm Capsules
OxyNorm is an immediate-release oral formulation of oxycodone, a mu-opioid receptor agonist that binds to opioid receptors in the central nervous system to produce analgesia and other opioid effects.
OxyNorm is an immediate-release oral formulation of oxycodone, a mu-opioid receptor agonist that binds to opioid receptors in the central nervous system to produce analgesia and other opioid effects. Used for Moderate to severe acute pain, Breakthrough pain in opioid-tolerant patients.
At a glance
| Generic name | OxyNorm Capsules |
|---|---|
| Also known as | OxyNorm |
| Sponsor | Mundipharma (China) Pharmaceutical Co. Ltd |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Oxycodone works by activating mu-opioid receptors throughout the brain and spinal cord, which modulates pain perception and emotional response to pain. The immediate-release capsule formulation allows rapid onset of analgesia, making it suitable for acute pain management and breakthrough pain in opioid-tolerant patients.
Approved indications
- Moderate to severe acute pain
- Breakthrough pain in opioid-tolerant patients
Common side effects
- Constipation
- Nausea
- Dizziness
- Drowsiness
- Vomiting
- Pruritus
- Respiratory depression
Key clinical trials
- NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers (PHASE3)
- OxyNorm® Capsules (Immediate-Release) Pharmacokinetic (PK) Study (PHASE1)
- Effects of Tapentadol Versus Oxycodone After Hysterectomy. (PHASE4)
- OxyNorm Capsules in Post-Operative Pain Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OxyNorm Capsules CI brief — competitive landscape report
- OxyNorm Capsules updates RSS · CI watch RSS
- Mundipharma (China) Pharmaceutical Co. Ltd portfolio CI